Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis
- 12 September 2008
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 22 (14) , 1759-1767
- https://doi.org/10.1097/qad.0b013e32830a5043
Abstract
To establish the effectiveness of cidofovir for AIDS-related progressive multifocal leukoencephalopathy (PML) in patients concomitantly receiving combination antiretroviral therapy. Analysis of raw data pooled from one prospective and five cohort studies. Tertiary care centers for the treatment of HIV-associated complications. Three hundred seventy HIV-infected PML patients diagnosed from 1996 treated with combination antiretroviral therapy with or without cidofovir. All studies had already published their results but for four of them, additional patients and follow-up data are included in this report. Follow-up was started from the date of first abnormal neuroimaging; those treated with cidofovir were entered at risk at the date of cidofovir initiation. Main study outcomes were time to PML-related death and odds of 12-month moderately severe to severe disability (Rankin score ≥4). Sixty-four percent of the PML cases were confirmed by histopathology or JC virus DNA detection in cerebrospinal fluid; 185 (50%) received cidofovir (median five cycles). During 463 person-years of follow-up, 167 PML-related deaths occurred (36.6 per 100 person-years of follow-up). Estimated 1 year survival was 0.56 (95% confidence interval, 0.50–0.61). In multivariate models stratified by cohort and adjusted for type of diagnosis and relevant prognostic confounders, cidofovir treatment was not associated with survival (hazard ratio for death 0.93, 0.66–1.32). Results were similar using time to death from any cause as the outcome. Furthermore, 12-month moderately severe to severe disability was not associated with the use of cidofovir. In combination antiretroviral therapy-treated PML patients, cidofovir use did not influence PML-related mortality or residual disability. New treatments for AIDS-related PML are urgently needed.Keywords
This publication has 36 references indexed in Scilit:
- Prognostic Significance of JC Virus DNA Levels in Cerebrospinal Fluid of Patients with HIV-Associated Progressive Multifocal LeukoencephalopathyClinical Infectious Diseases, 2005
- The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDS‐Associated Progressive Multifocal LeukoencephalopathyThe Journal of Infectious Diseases, 2000
- Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitorsAIDS, 1999
- Progressive Multifocal Leukoencephalopathy: Improved Survival of Human Immunodeficiency Virus–infected Patients in the Protease Inhibitor EraThe Journal of Infectious Diseases, 1999
- Notes Progressive Multifocal Leukoencephalopathy in Patients with AIDS Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 1999
- HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyNeurology, 1999
- Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapyAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- The Natural History of Progressive Multifocal Leukoencephalopathy in Patients with AIDSClinical Infectious Diseases, 1995
- Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus InfectionAnnals of Internal Medicine, 1987